Metamorphx is emerging as a leading natural GLP-1 alternative for weight loss in 2025. With prescription options like ...

A large study in older adults with type 2 diabetes finds that GLP-1 receptor agonists are associated with a modestly ...

Today, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) submission for an investigational once-daily, 25 mg oral formulation of Wegovy® ...

Innovent Biologics is planning a second filing for its dual GLP-1/glucagon agonist mazdutide in China, as it tries to carve out a share of a market currently dominated by Novo Nordisk and Eli Lilly.

Scientists have discovered a gut microbe and its metabolites that can naturally regulate blood sugar levels and sugar ...

Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first-quarter of 2025.

SHOPPING: If you're ready to meet your weight goals, turn to Hims for personalized weight loss treatments that are ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial published in The New England Journal of Medicine.

The Trump administration this April scrapped a Biden-era proposal that would have required state Medicaid programs and allowed federal Medicare to pay for some GLP-1s for obesity treatment. Instead, ...

More than 2.5 billion adults worldwide are currently overweight or obese, according to estimates from the World Health Organization.

Kyle Richards ' 25-year-old daughter Sophia Umansky has shared a "graphic" video of the extensive hair loss she has suffered after taking a weight loss drug for four months.

In 2023, experts decided against adding obesity drugs to the World Health Organisation's essential medicines list.